lipid-specific IgM bands in csf associated with a reduced risk of developing pml during treatment with natalizumab. Villar LM, Costa-Frossard L, Masterman T, Fernandez O, Montalban X, Casanova B, Izquierdo G, Coret F, Tumani H, Saiz A, et al. Ann Neurol. 2015 Jan 7. PMID: 25581547. Abstract CommentRecommendBookmarkWatch